Editor
A GROUP OF rich do-gooders tried a bold experiment 15 years ago. The Gates Foundation, a charity, and five countries put $1.5bn into a pilot project aimed at encouraging research and development in a previously neglected area. The “advanced market commitment” (AMC) they created promised rewards to drugmakers that came up with an effective vaccine against pneumococcus, a disease which killed many children in poor countries. Defying…
